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Abstract
Central sensitization elicits pain hypersensitivity and is thought to be causally implicated in
painful temporomandibular disorder (TMD). This causal inference is based on cross-sectional
evidence that people with TMD have greater sensitivity than controls to noxious stimuli. We
tested this inference in the OPPERA prospective cohort study of 3,258 adults with no lifetime
history of TMD when enrolled (Visit 1). During five years of follow-up, one group labelled
“persistent TMD cases” (n=72) developed first-onset TMD by Visit 2 that persisted ≥6 months
until Visit 3. Another group labelled “transient TMD cases” (n=75) developed first-onset TMD at
Visit 2 which resolved by Visit 3. Randomly sampled “controls” (n=126) remained TMD-free
throughout all three visits. At each visit, pressure pain thresholds (PPTs) were measured by
algometry at 10 cranial and bodily sites. In persistent TMD cases, mean PPTs reduced 43 kPa
(P<0.0001) between Visits 1 and 2 and thereafter did not change significantly. In transient TMD
cases, mean PPTs reduced 41 kPa (P<0.001) between Visits 1 and 2, and then increased 20 kPa
(P<0.001) by Visit 3. These patterns were similar after excluding cranial sites symptomatic for
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TMD. Importantly, Visit 1 PPTs had no clinically useful prognostic value in predicting first-onset
TMD (odds ratio [OR] 1.07, P=0.15). Among first-onset cases, Visit 2 PPTs were modest
predictors of persistent TMD (OR=1=.36, P=0.002). In this longitudinal study, PPTs reduced
when TMD developed then rebounded when TMD resolved. However, pre-morbid PPTs poorly
predicted TMD incidence, countering the hypothesis that they signify mechanisms causing first-
onset TMD.
Keywords
Temporomandibular disorder; epidemiology; pressure pain thresholds; algometry; longitudinal
studies
Introduction
Pain thresholds vary markedly among people when blunt pressure is applied to their muscles
and joints. Low pressure pain thresholds (PPTs) may signify a generalized state of pain
sensitivity, variously attributed to altered sensory processing, dysregulated endocrine
function, hyperinflammatory states, or psychological processes.[13] There is strong support
for a role of central sensitization, defined as “amplification of neural signaling within the
CNS that elicits pain hypersensitivity”.[31] Central sensitization, in turn, is a putative cause
of clinical pain syndromes including temporomandibular disorder (TMD).[31] Hence,
pressure algometers, which provide a simple and non-invasive method to assess PPTs, are
recommended for clinical care and research with TMD patients.[26]
Most evidence supporting a relationship between PPTs and clinical pain comes from studies
using cross-sectional designs.[4; 5; 15; 19; 21; 22; 27] In one landmark case-control study,
PPTs at facial locations were lower in patients with TMD than in TMD-free controls,
irrespective of whether or not the location was symptomatic for TMD.[19] The investigators
concluded that TMD was a consequence of general sensitization to otherwise normal
sensations in the orofacial region and that centrally-mediated pain played a role “in either
the onset or perpetuation of myogenous TMD”.[19] Similar interpretations are reported in
other cross-sectional studies of widespread pain.[13]
Fewer longitudinal studies have investigated PPTs and clinical pain, and their conclusions
vary. In one study, pre-morbid PPTs were lower in people who later developed clinical
shoulder pain than in people who did not.[14] In contrast, a prospective study of tension-
type headache found that pre-morbid PPTs did not predict its development.[2] Another study
found that low PPTs did not predict development of widespread pain.[9] Prospective studies
of people with acute whiplash injury report conflicting findings regarding the prognostic
value of PPTs in predicting recovery.[11; 30]
Recently, we reported results from a prospective study of first-onset TMD that was part of
the OPPERA project (Orofacial Pain: Prospective Evaluation and Risk Assessment).[7] Pre-
morbid PPTs measured at enrollment were significant predictors of TMD incidence,
although the effect was much weaker than the cross-sectional association between PPTS and
chronic TMD in the OPPERA baseline case-control.[8] However, in the prospective study,
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we did not analyze changes in PPTs between enrollment and development of TMD, and we
did not distinguish TMD that was transient from TMD that became persistent.
To address these gaps, the current study reports findings from PPTs measured in the
OPPERA cohort before, during and after the development of clinical TMD. The first aim
was to compare changes in PPTs between three groups: people who developed persistent
TMD, people who developed transient TMD, and controls who remained free of TMD
throughout the study. The second aim was to evaluate whether PPTs are useful clinically,
either in predicting a person's risk of developing TMD or as a concurrent biomarker to
discriminate between people who have TMD from people who do not. These aims do not
consider potential interactions between PPTs and other risk factors for TMD which, instead,
will be investigated in subsequent analysis of OPPERA data.
Methods
This paper reports findings from a nested case-control study of first-onset TMD that was
part of the OPPERA project. Previous papers have described the relationship between this
nested study and two other components of the OPPERA project: the baseline case-control
study of chronic TMD [23] and the OPPERA prospective cohort study of first-onset TMD.
[1] The following sections adopt STROBE guidelines [29] to elaborate on the nested study's
design, setting, participants, variables, sample size justification and statistical analyses. All
OPPERA study participants provided signed, informed consent to participate. The project
was reviewed and approved by institutional review boards at each study site. Privacy of
research participants is further protected by a Certificate of Confidentiality (NIDCR-06-17)
between the National Institutes of Health and Dr. William Maixner, Program Director of
OPPERA.
Study design
Nested case-control studies combine the efficiency of the case-control design with the
strengths of longitudinal data from a prospective cohort study. Typically they collect
additional new data from cohort members who develop the disease of interest (cases) and a
subset of cohort members who remain disease-free (controls).[12] In the current study, cases
were all participants in the OPPERA prospective cohort study who developed first-onset
TMD and controls were an approximately equal number of participants who did not develop
TMD.
Study setting and enrollment screening criteria
Between May 2006 and November 2009, the OPPERA prospective cohort study enrolled
community-dwelling adults who had no significant history of TMD. Participants were
recruited using advertisements, emails and flyers distributed in communities surrounding the
four U.S. study sites: Baltimore, MD; Buffalo, NY; Chapel Hill, NC; and Gainesville, FL.
Details of the study settings and study participants are reported elsewhere.[1] In summary,
screening selection criteria were used to select volunteers who had all of the following
characteristics: aged 18-44 years; English language fluency; intention to live in the area for
at least two years; fewer than five headaches/month in the three months before enrollment;
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no history of significant TMD symptoms (that is, no orofacial pain in the month before
enrollment and, prior to that period, no more than four days of orofacial pain per month); no
prior diagnosis or treatment for TMD; and absence of 13 specific health conditions.
Clinical examination to select TMD-free participants at enrollment (Visit 1)
Volunteers who met screening selection criteria were asked to complete 15 questionnaires
about psychological characteristics and health status [23] prior to their attendance at an
OPPERA research clinic for a three-hour baseline assessment (Visit 1). The comprehensive
examination protocol, adapted from the Research Diagnostic Criteria for TMD,[3] excluded
participants found to have clinical TMD. Specifically, potential participants were excluded if
they met either one of two criteria: 1) history of pain in the orofacial region for ≥5 days in
the prior 30 days; and 2) evoked pain in ≥3 muscle locations (myalgia) or in ≥1
temporomandibular joints (arthralgia). For the second criterion, study participants performed
standardized jaw movements while examiners manually palpated ten anatomical locations:
temporalis, masseter, lateral pterygoid and submandibular muscles and the
temporomandibular joints (TMJs), each assessed bilaterally. Examiners were trained in the
diagnostic criteria prior to study initiation and they had excellent inter-examiner reliability
when compared to the study's reference examiner.[1] Using these procedures, 3,258 TMD-
free subjects were enrolled into the prospective cohort study (Figure 1).
Follow-up screening and Visit 2 examinations to select cases and controls for the nested
study
At three month intervals after enrollment, study participants completed a screening
questionnaire that asked about TMD symptoms. Subjects reporting symptoms were invited
to return to the respective research clinics for a follow-up assessment (Visit 2). Examiners
followed the same comprehensive examination protocol to determine presence or absence of
TMD using the criteria applied at Visit 1. In addition, participants with TMD completed
questionnaires that included Gracely's ratio scales of facial pain unpleasantness and intensity
during the preceding month.[6]
As each incident case was confirmed, one control was sampled at random from among the
remaining symptom-free cohort members. Sampled controls were likewise invited to
research clinics where examiners verified absence of clinical TMD. The median period
between Visit 1 and Visit 2 examinations was 17 months (interquartile range=10-26
months). The sampling design matched cases and controls according to four criteria: 1)
enrollment within 15 days of one another; 2) quarterly questionnaires completed within
three months of one another; 3) same gender; and 4) enrollment at the same study site. The
first two criteria created similar periods of follow-up for cases and controls, which is a
requirement of the nested case-control design. Gender was a matching criterion because we
expected greater TMD incidence in females than males. Study site matching was desirable
to control for extraneous site-specific factors that are inherent in multi-site studies. Through
May 2011, these procedures selected 456 participants for the nested case-control study
including 235 participants who reported symptoms and were diagnosed with first-onset
TMD and 221 matched controls (Figure 1). Among the matched controls, 25 had TMD
when examined, resulting in 260 incident cases of first-onset TMD and 196 TMD-free
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controls. Excluded from this analysis were 159 Sub-clinical TMD participants who reported
symptoms but who were negative for TMD when examined and 84 participants who
reported symptoms but did not attend the examination (Figure 1).
Follow-up clinical examination to determine TMD persistence at Visit 3
Approximately six months after the Visit 2 examination, all participants in the nested case-
control study were asked to return to research clinics for a third examination (Visit 3). The
median period between Visit 2 and Visit 3 examinations was 8 months (interquartile
range=6-15 months). The variability reflects our decision to make all possible efforts to re-
examine participants in the nested case-control study, even when appointments had to be
postponed or rescheduled. Of the 147 incident cases re-examined at Visit 3, 72 (49%) had
examiner-verified TMD and were labeled “persistent TMD” cases. We recognize that the
duration of their TMD pain exceeds the six-month threshold used by the International
Association for the Study of Pain[18] as the criterion to classify pain as chronic. However,
we avoid the label “chronic” on the grounds that it is more appropriately classified using
other dimensions in addition to duration[6] that were not assessed in this study. The
remaining 75 participants (51%) who no longer had examiner-verified TMD were labeled
“transient TMD” case (Figure 1). Virtually all (126/127) of the controls who were re-
examined at Visit 3 remained free of clinical TMD.
Algometry measurements of pressure pain thresholds (PPTs)
At each visit to research clinics, PPTs were measured using a pressure algometer. As
described fully elsewhere,[8] bilateral measurements recorded at five anatomical locations
(temporalis muscles, masseter muscles, TMJs, trapezius muscles, and the lateral
epicondyles) yielded 10 measurements. Pressure was increased at the rate of 30 kPa per
second until either the participant indicated first pain sensation, or until 600 kPa was
applied. Measurements were repeated at each location either until two values were obtained
within 20kPa of one another or until five trials were administered. The two closest values
were then recorded.
Variables used in this analysis
For each study participant, repeated PPTs at left and right sides were averaged to produce
five mean values, one for each pair of muscles or joints. For consistency with methods used
in previous studies, these calculations included all threshold values (n=4,014 values in 273
participants who attended all three visits). This included PPTs recorded at the cranial sites in
which participants reported TMD-like pain that was evoked during clinical examination
procedures. However, to create a measure of PPT that was not contaminated by TMD
symptoms, we computed an additional outcome variable that excluded temporalis, masseter
or TMJ measurements if pain was evoked at the same location during the clinical
examination (n=3,073 values in 273 participants). Hereafter, we refer to them as PPTs at
non-symptomatic sites.
Demographic characteristics of gender, age, race and ethnicity were self-reported in
screening interviews at the time of enrollment. Age was categorized into three groups for
descriptive purposes and used as a continuous variable (in years) for statistical models.
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Questions about race and ethnicity were combined to form three groups: non-Hispanic
White, African-American, and other or unstated racial-ethnic groups. For aim 2, each
participant's interval between study visits was computed as the number of days between
visits. Study site was a categorical variable denoting the study site at which participants
were enrolled: FL, MD, NC, or NY.
Statistical analysis
For descriptive purposes, univariate statistics described the distribution of PPTs at each
anatomical location and unadjusted means were compared among demographic groups. To
test hypotheses for Aim 1, data were analyzed for the 273 participants who completed all
three visits and adjusted means were computed using a general estimating equation (GEE)
linear regression model. The model allowed for within-subject measurements that were
repeated across visits and, within visits, at five anatomical locations. Explanatory variables
in the model were study-group (3 categories: persistent TMD cases, transient TMD cases,
and controls), visit (3 categories), study-group × visit interaction and four adjustment
variables: study site (4 categories), age (continuous variable), gender (2 categories), race-
ethnicity (3 categories). The interaction term was included to allow the pattern of PPTs
across visits to vary according to study group (that is, persistent TMD, transient TMD, and
controls). Demographic variables were included in the models because the descriptive
analysis revealed they were associated with PPTs. Study site was a covariate to control for
extraneous factors that differ between sites in multi-site studies. We used GEE models in
preference to repeated measures analysis of variance because GEE models use all available
data, even for subjects who have missing data for one or more anatomical locations and/or
visits. GEE models were created using the “genmod” procedure in SAS version 9.3,
specifying an exchangeable working correlation matrix for within-subject measures.
Adjusted means and standard errors were calculated using the “lsmeans” statement, while
between-study-group and between-visit contrasts were calculated using the “lsmestimate”
statement. When plotting means, reference values for chronic TMD cases were also
displayed, based on values reported in the OPPERA baseline case-control study.[8]
The analysis for Aim 2 used mixed effect, unconditional binary logistic regression models to
predict odds of clinical TMD, both at Visit 2 (n=456 participants with Visit 1 and Visit 2
data) and at Visit 3 (n=273 participants with Visit 2 and Visit 3 data). The unconditional
method was used, thereby ignoring the matched sampling design, because many pairs were
incomplete due to non-examination of one pair member and because some participants
selected as controls were found to be cases when examined (Figure 1). To aid in
interpretation of prediction models, PPTs were transformed to negative z-scores. This was
done separately for each anatomical location by subtracting the observed PPT from the
sample mean for that anatomical location, and dividing the result by the standard deviation
for that anatomical location. The resulting odds ratios therefore can be interpreted as the
change in odds of TMD associated with a one standard deviation decrease in the PPT (that
is, greater pain sensitivity). The fixed-effect, predictor variable was the z-transformed PPT,
and there were five adjustment variables: interval between visits (continuous variable), study
site (4 categories), age (continuous variable), gender (2 categories) and race-ethnicity (3
categories). Random effects were anatomical location nested within person. Odds ratios
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(ORs) and their 95% confidence limits (95% CLs) were calculated as measures of the
strength of association between PPTs and odds of TMD. The ability of PPT to discriminate
between cases and controls was indexed using the PPT's contribution to the area under the
receiver operating characteristic curve (AUROC). To be “useful” for clinical diagnostic
purposes, values of AUROC should exceed a threshold of 0.7, while values exceeding 0.9
are regarded as “excellent”.[28] Mixed models were created using the “glimmix” procedure
in SAS version 9.3, specifying a variance components covariance structure for the random
effects. Mixed models were used because, in general, they are more appropriate for
estimating subject-specific effects than GEE models, which are preferred for population-
level effects.[10] We therefore used GEE models for Aim 1, where the focus was on mean
changes in PPTs for the population from which study participants were selected, whereas
mixed effect models were used for Aim2, which had a focus on predicting individuals' odds
of clinical TMD.
Three different prognostic models were created: a) PPTs at visit 1 were used to predict odds
of first-onset TMD at Visit 2; b) PPTs at visit 1 were used to predict odds of either persistent
TMD (i.e., TMD classified both at Visit 2 and Visit 3) or transient TMD (i.e., TMD
classified at Visit 2 and absence of TMD classified at Visit 3); and c) among participants
with first-onset TMD, PPTs at Visit 2 were used to predict odds of persistent TMD at Visit 3
(i.e., TMD classified both at Visit 2 and Visit 3). Meanwhile, two models were created to
evaluate associations with concurrent case-classification: d) PPTs at Visit 2 were used to
predict odds of first-onset TMD at Visit 2; e) PPTs at Visit 3 were used to predict odds of
persistent TMD at Visit 3.
Because the label “TMD” represents a cluster of clinical disorders that cause orofacial pain,
we created sub-classifications of TMD to further investigate potential prognostic and
concurrent associations of PPTs with specific types of TMD. One sub-classification
distinguished between arthralgia alone, myalgia alone, and combined arthralgia + myalgia.
Another sub-classification distinguished between TMD cases who reported low (below
median) versus high (median or above) ratings of pain unpleasantness. A third sub-
classification distinguished between TMD cases who reported low versus high ratings of
pain intensity.
We also explored the possibility that pain in other parts of the body might affect PPTs,
thereby modifying observed relationships between PPTs and TMD. Responses to baseline
questionnaires about health status were used to classify four pain-related conditions: a) the
number of different types of headache during the preceding year; b) low back pain during
the preceding year; c) irritable bowel syndrome; and d) a checklist of 20 comorbid
conditions related to pain, ranging from arthritis to sleep apnea. The four were chosen
because all were strong predictors of TMD in the OPPERA baseline case-control study [18]
and the OPPERA prospective cohort study of TMD incidence.[20]
For both aims, the threshold for statistical significance was P<0.05 based on two-tailed tests.
Inferences about clinical significance were based on the magnitude of mean differences
(Aim 1) and effect measures (odds ratios and AUROC).
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In the OPPERA prospective cohort study the target sample size was 3,200 enrollees because
that number was expected to yield 196 cases of first-onset TMD during a three-year follow-
up period. Calculations made when designing the study indicated that those numbers would
provide 80% statistical power to detect risk ratios of at least 1.8 for risk predictors with as
few as 15% of people in the high-risk category.[1] Post-hoc calculations were made for the
454 participants in this nested case-control study who were examined at Visit 2, revealing
80% power to detect differences in PPTs between cases and controls that were as small as
0.27 standard deviations. For the 273 participants in the nested case-control study seen at all
three visits, the corresponding minimum difference was 0.35 standard deviations.
Results
Upon enrollment in the OPPERA prospective cohort study, the 3,258 TMD-free study
participants ranged in age from 18 to 44 years (mean=27 years), 57% were female and 50%
were non-Hispanic Whites. Through May, 2011, 478 enrollees reported TMD symptoms in
at least one follow-up questionnaire, 2,259 reported no symptoms, and 521 enrollees
completed no follow-up questionnaires (Figure 1). Examinations at Visit 2 identified 456
participants eligible for the nested case-control study (260 first-onset cases and 196 TMD-
free controls). However, 182 (113 cases and 69 controls) did not attend the Visit 3
examination and one control at Visit 2 who developed TMD at Visit 3 was excluded. Thus
273 participants in the nested case-control study had data from all three visits. Excluded
from the analysis were 159 “Subclinical TMD” particpiants who reported symptoms but
who were found by examiners not to have TMD at Visit 2.
In most instances, mean PPTs in groups lost to follow-up were similar to the larger group
from which they originated.(Appendix Figure 1) For example, mean PPTs at cranial sites for
the 521 participants who completed no follow-up questionnaires were within 5 kPa of means
for all enrollees at Visit 1. When larger differences were found, they tended to be PPTs from
bodily sites. For example, the aforementioned groups differed by 16 kPa in mean trapezius
PPTs, and by 19 kPa in mean lateral epicondyle PPTs. Previous analysis of demographic
patterns in cohort retention showed that loss to follow-up was greater among males than
females, and among African Americans compared to other racial-ethnic groups.[1]
Among all 456 participants who at least completed Visits 1 and 2, mean PPTs at Visit 1
varied significantly according to age, gender and race-ethnicity for at least one anatomical
location (Table 1). The largest variation was between genders, where the lateral epicondyle
PPT was 100 kPa (23%) lower in females than in males. Females also had significantly
lower PPTs at all other anatomical sites. The general similarity of demographic associations,
regardless of anatomical location, was consistent with strong correlations observed between
all pairs of PPTs (Appendix Table 1).
In the analysis of PPTs from all five anatomical sites in participants who completed all three
visits, the three study groups displayed distinctive temporal patterns in mean PPTs (Figure
2A). Differences in temporal patterns among groups were evidenced by a statistically
significant (P<0.001) interaction between study group and visit in the GEE model used to
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calculate adjusted means. For those who became persistent cases, the mean PPT of 256 kPa
at enrollment reduced by 43 kPa (17%; P<0.001) at the time of first-onset TMD, and
increased by only 9 kPa (4%; P=0.056) by Visit 3. For those who developed transient TMD,
the mean PPT of 270 kPa at enrollment reduced by 41 kPa (15%; P<0.001) at the time of
first-onset TMD, but increased by 20 kPa (9%, P<0.001) at Visit 3, when the TMD had
remitted. Among controls, differences between visits were statistically significant, though
small in magnitude, varying by no more than 10 kPa (4%) between visits. The patterns were
strikingly similar when data were restricted to PPTs recorded at non-symptomatic sites
(Figure 2B).
Table 2 quantifies the changes depicted in Figure 2 and includes additional contrasts in PPTs
between study groups. Of note, Visit 1 PPTs were 20 kPa lower (8%, P=0.003) in
participants who became persistent cases compared to Visit 1 PPTs in controls. However,
Visit 1 PPTs in participants who became transient cases were only 2 kPa lower than Visit 1
PPTs in controls (P=0.747). Although not included in Table 2, participants with Subclinical
TMD at Visit 2 had PPT values at Visit 2 (mean=245.8, standard error=7.9, n=159
participants) that that were intermediate between controls and the two groups of TMD cases
at the same visit (Table 2). For the Subclinical TMD participants, this represented a 7%
reduction (P<0.001) of their Visit 1 PPTs (mean= 263.8, standard error=7.8).
The temporal pattern was similar using mean PPTs for each of the five anatomical locations
(Appendix Fig 2A-2E). In general, PPTs reduced considerably at the time of first-onset
TMD and for persistent cases, PPTs did not change significantly thereafter. In contrast,
among transient cases, PPTs increased upon remission of TMD. One exception to this
general pattern was seen at the lateral epicondyle (Appendix Fig 2E) where PPTs did not
increase between Visits 2 and 3 in transient cases. However, temporal patterns among study
groups did not differ to a statistically significant degree across body sites, as evidenced by a
separate GEE model that added a three way interaction of location × study group × visit (for
the interaction's score statistic, Chi-square = 19.7, degrees of freedom=16, P=0.2339).
Using data from all anatomical sites, pre-morbid (i.e., Visit 1) PPTs were, at best, weak
predictors of TMD incidence (Table 3). For the 456 participants with at least two visits,
Visit 1 PPTs were not significantly associated with odds of first-onset TMD at Visit 2
(OR=1.07, 95%CL = 0.98, 1.17) and were no better than chance (AUROC=0.50) at
discriminating between incident cases and controls. Visit 1 PPTs were statistically
significant, but modest, predictors of persistent TMD at Visit 3, (OR=1.18, 95%CL = 1.00,
1.38) and discrimination was poor (AUROC=0.53). However, among participants who
developed first-onset TMD, Visit 2 PPTs were statistically significant predictors of
persistent TMD at Visit 3, although the effect was only of modest clinical significance
(OR=1.36, 95%CL=1.11, 1.66; AUROC=0.54). Meanwhile, there were statistically-and
clinically-significant concurrent associations between PPTs and TMD case-classification
(Table 4). PPTs measured at Visit 2 had a moderately strong concurrent association with
first-onset TMD at Visit 2 (OR= 2.62, 95%CL = 2.32, 2.95; AUROC=0.66). The concurrent
association between Visit 3 PPTs and TMD case-classification at Visit 3 was also
statistically significant although not as strong (OR=1.93, 95%CL=1.62, 2.30;
AUROC=0.61).
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Analysis of TMD sub-classifications did not appreciably alter the findings. Visit 1 PPTs
were weak and statistically-non-significant predictors of all three anatomical sub-
classifications at Visit 2: myalgia alone (n=62 TMD cases), arthralgia alone (n=10 TMD
cases) and mixed arthralgia+myalgia (n=188 TMD cases; Model 1, Appendix Table 2).
However, Visit 2 PPTs were strongly associated with each of the anatomical sub-
classifications at Visit 2 (Model 2, Appendix Table 2). Likewise, Visit 1 PPTs were equally
weak predictors of TMD with high pain unpleasantness and TMD with low pain
unpleasantness (Model 3, Appendix Table 2). The same was true when TMD was sub-
classified according to pain intensity (Model 4, Appendix Table 2). However, for the
concurrent associations at Visit 2 PPTs, low thresholds were more strongly associated with
the sub-types that had more severe symptoms at Visit 2 (Models 5 and 6, Appendix Table 2)
While considerable numbers of study participants at enrollment reported headache, low back
pain, irritable bowel syndrome, or comorbid pain-related conditions, PPTs at Visit 1 were
not systematically associated with those conditions (Appendix Table 3). Mean PPTs at four
anatomical sites varied according to the number of different types of headaches, with
nominal P-values ranging from 0.010 to 0.048. However there was no consistent direction in
the relationship: PPTs were greatest among participants with no headaches or with ≥4 types
of headache, whereas PPTs were lower for participants with intermediate numbers of
headache types. Other conditions were associated with mean PPTs in expected directions,
but P-values ranged from 0.082 to 0.750. Furthermore, none of the P-values in Appendix
Table 3 achieved the threshold of statistical significance after adjusting for the 20 tests.
Overall, the findings suggested that previously noted associations between PPTs and TMD
were unlikely to be altered by these pain-related conditions.
Discussion
In this community-based, longitudinal study of U.S. adults, PPTs fluctuated in synchrony
with the course of painful TMD. Compared to pre-morbid values recorded at enrollment,
PPTs decreased significantly at the time of first-onset TMD ascertainment. PPTs remained
lowered in the group whose clinical TMD persisted. However in those whose TMD pain
resolved, PPTs increased to near pre-morbid levels. When viewed cross-sectionally, we
found moderately strong, concurrent associations between TMD case-classification and
PPTs determined at the same visit. However, the novel contribution of this study is that pre-
morbid PPTs had no clinically-useful prognostic value in predicting who would and who
would not develop first-onset TMD. Specifically, AUROC values were well below the
benchmark of 0.7,[28] meaning that, for a given PPT value, the true-positive proportion of
TMD cases was not much greater than the false-positive proportion. At best, PPTs at the
time of first-onset TMD were statistically significant, though modest, predictors of TMD
becoming persistent. The general lack of prognostic utility challenges the prevailing
hypothesis that pre-morbid sensitivity to pressure pain is indicative of sensitized pain
pathways that contribute causally to the risk of developing painful TMD. This conclusion
assumes that complex pain conditions have multiple causes, none of which are necessary or
sufficient. Instead, we adopt the epidemiologic concept of a cause as something which,
when blocked or removed, results in less disease within a population.[20]
Slade et al. Page 10






















Loss to follow-up is a concern in all longitudinal studies, particularly when it is associated
with characteristics used to test study hypotheses. In this study, most PPT measurements at
Visit 1 were not associated with loss to follow-up, although lateral epicondyle PPTs tended
to be lower in people lost to follow-up. Meanwhile, PPT changes between visits in the
persistent TMD group appeared different at the lateral epicondyle compared to other
anatomical locations. While this finding might suggest anatomical specificity in the
relationship between PPTs and TMD, we are reluctant to endorse the idea because of
potential loss to follow-up bias, and because the three-way interaction of location × study
group × visit was not statistically significant.
Different patterns of TMD may have been observed had study participants been followed for
longer periods than the median 17 months between Visits 1 and 2, or the median 8 months
between Visits 2 and 3. Another limitation was that PPTs were measured only at clinic
visits, not continually throughout the study. Clinic visits were scheduled as soon as possible
after symptoms were reported, although in practice, there was a median delay of 14 days.[1]
PPTs therefore could have reduced before being measured at Visit 2, and possibly even
before TMD developed. If the latter occurred, the true prognostic value of PPT
measurements would be underestimated in this study. However, continual monitoring of
PPTs at home is not feasible. Furthermore, if reductions in PPTs were informative only
within a window of a few weeks, the information would have little utility in most clinical
settings. For these reasons, we believe that current study provides a realistic testing ground
and justifies our overall conclusion that pre-morbid PPT measurements are not useful
clinical predictors of first-onset TMD.
This analysis was limited to PPTs because our previous analyses found them to be strongly
associated with clinical TMD.[7; 8] In contrast, temporal summation of mechanical
cutaneous “pinprick” stimuli was only weakly associated with chronic TMD in the baseline
case-control analysis[8] and it did not predict incidence of TMD.[7] Meanwhile, temporal
summation of thermal stimuli was not associated with chronic TMD [8] and was only
weakly associated with TMD incidence.[7] Both findings were surprising because temporal
summation is a more specific indicator than PPTs of central sensitization. However, effects
of temporal summation on clinical pain appear to be complex: we have since re-analyzed the
baseline case-control study and found that associations between temporal summation and
TMD were dependent on initial sensitivity to thermal pain. In this paper, we therefore
focused on PPTs, expecting them to have greatest prognostic value for changes in clinical
TMD.
While the overall weak prognostic value of pre-morbid PPTs was unexpected, the finding
has precedents in studies of other idiopathic pain syndromes. In a community-based study of
674 Danes followed for 12 years, 63 developed headache, but PPTs measured at enrollment
did not predict risk of developing headaches[2]. However, PPTs decreased at follow-up in
subjects who developed chronic tension-type headache over the 12-year period, a result that
mirrors the changes seen here in people who developed first-onset TMD. In another
community-based study, 170 Danish adults were followed for 8 years and 57 developed low
back pain, although baseline PPTs did not predict risk of its development.[17] In a
community-based study of 228 U.K. adults, PPTs measured at enrollment were not
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significant predictors of widespread pain development.[9] However, other studies have
found that PPTs can predict clinical pain. A longitudinal study of 12 newly-employed
female process workers found that PPTs at enrollment were significantly lower for the six
who developed shoulder pain six months later compared to the six who did not.[14] A study
of 35 diabetic patients undergoing lower limb amputation found that pre-operative PPTs
measured at the limb to be amputated were weak predictors of post-operative pain intensity
after one week but did not predict pain after six months.[16] Overall, while the findings
from small, selected study samples indicate that low PPTs can have modest, short-term
prognostic value, results from larger community-based studies suggest that they have little
prognostic value in the population at large.
In the current study and in the longitudinal studies noted above, the distinction between first-
onset pain and persistent pain was based solely on the duration of clinical pain. While time
is the one criterion used in some taxonomies to define chronic pain,[18] it arguably is not
sufficient. If, in addition, chronic pain is “perpetuated by factors that are both pathogenically
and physically remote from the originating cause”,[6] it is likely that some of the persistent
TMD cases in this study would not qualify as cases of chronic pain. This is supported by the
observation that mean PPTs in persistent cases were never as low as the mean PPTs in
chronic TMD cases from the OPPERA baseline case-control study. Of note, these persistent
cases had experienced TMD for up to a year, whereas most of the chronic cases reported
TMD of at least three years duration.[23] It follows that low-premorbid PPTs might yet
prove to be useful clinical predictors for a subgroup of these persistent cases who develop
truly chronic pain. To investigate that possibility, future studies of longer duration will need
to evaluate a broader set of pathogenic factors contributing to this complex pain condition.
The current study has three major strengths. Firstly, the sample size of 260 incident cases of
first-onset TMD far exceeds numbers of incident cases reported in other longitudinal studies
noted above. Secondly we had analytic flexibility to select only anatomical locations that
were non- symptomatic for TMD. This revealed that pressure pain sensitivity was not
merely a consequence of TMD symptoms, but was generalized to other anatomical
locations. The third major strength was measurement of PPTs at three points in time. This
gave rise to the novel finding that low PPTs at the time of first-onset TMD were modestly
predictive of persistent TMD. Although the corresponding AUROC value was well below
the designated benchmark for “useful” clinical prediction,[28] the result suggests that low
PPTs may offer some etiologic insight into the transition from acute to chronic pain. We
caution, however, that this possibility needs to be reconciled with the weaker effect of pre-
morbid PPTs in predicting persistent TMD. One possibility is that low PPTs in an
asymptomatic person signifies a trait predisposing the person to alterations in central
nociceptive pathways. In someone with this predisposition, the first-onset of painful TMD
then serves as a trigger to increase synaptic efficacy of neurons in central nociceptive
pathways which is the hallmark of central sensitization.[31] The idea that clinical pain might
be a trigger is supported by findings from an experimental study of 28 women with
fibromyalgia showing that peripheral mechanisms elicited central sensitization at the site of
injury.[25] This proposed combination of a predisposing trait and a triggering event is a
more nuanced interpretation than the general idea that central sensitization contributes to
clinical pain syndromes such as TMD. It adds support for the interpretation of Reid et al [19]
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that central mechanisms are involved in perpetuation of TMD, although it refutes their
suggestion that central mechanisms contribute to its onset.
In summary, while pre-morbid algometry measurements of PPTs were not useful in
predicting the clinical course of TMD, the measurements appear to provide insight into
mechanisms causing general sensitization in people with recent onset-TMD. That insight
should help clinicians and their patients understand that TMD pain symptoms can have
consequences that spread beyond the orofacial region.
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Figure 1. Flowchart of enrollment and follow-up in the OPPERA nested case-control study of
TMD incidence
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Adjusted mean pressure pain thresholds pooled from five anatomical locations measured at
three visits in each of three study groups: OPPERA nested case-control study of TMD
incidence. Data are from 72 persistent TMD cases who developed first-onset TMD at Visit 2
that persisted at Visit 3 (●), 75 transient TMD cases who developed first-onset TMD at visit
2 that remitted at Visit 3 (×) and 126 TMD-free controls (○). Adjusted means were
computed using a generalized estimating equation for within-subject measurements that
were repeated across visits and, within visits, across five anatomical sites. Covariates in the
model were: study-group (persistent TMD, transient TMD or control), visit (1, 2 or 3),
study-group × visit interaction and five adjustment variables: age (continuous variable),
gender (2 groups), race-ethnicity (3 groups), study site (4 groups) and anatomical location (5
groups). 2A shows adjusted means from all 4014 pressure pain thresholds while 2B shows
adjusted means from 3,073 pressure pain thresholds that excluded measurements made at
cranial sites in which participants reported TMD-like pain during clinical examination.
Symbols represent P-values testing the null hypothesis that the adjusted mean threshold at
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one visit is equal to the adjusted mean threshold at the preceding visit in the same study
group: ‡ P<0.01; † 0.01<P<0.05. * Reference values for chronic TMD are from Greenspan
et al, 2011. [8]
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